文献速递生殖医学

不明原因不孕的宫腔内人工授精网络荟萃分析

IUI for unexplained infertility-a network meta-analysis.
PubMed 文献 · Hum Reprod Update · 2020-01-01

该网络荟萃分析比较了自然周期及使用克罗米芬、来曲唑或促性腺激素刺激的宫腔内人工授精(IUI)对不明原因不孕夫妇的有效性与安全性,共纳入26项随机对照试验、5316名女性。结果显示促性腺激素组活产/持续妊娠率最高,但多胎妊娠风险亦高;严格取消标准下多胎率可接受且疗效不受损。

要点

  • 促性腺激素IUI活产/持续妊娠率优于克罗米芬(RR 1.39, 95%CI 1.09-1.76,中等质量证据)。
  • 促性腺激素IUI较自然周期多胎妊娠风险显著升高(RR 9.11, 95%CI 1.18-70.32)。
  • 严格取消标准下促性腺激素较克罗米芬活产/持续妊娠率RR 1.20(95%CI 0.95-1.51)。

核心结论

  • 基于低至中等质量证据,促性腺激素IUI在活产/持续妊娠率上排名最高,但多胎妊娠风险高。
  • 遵循严格取消标准的方案可获得可接受的多胎妊娠率而不影响有效性。
  • 在严格取消标准方案中,促性腺激素似乎较克罗米芬改善活产/持续妊娠率。

研究设计与样本

  • 研究为网络荟萃分析,检索PubMed、MEDLINE、EMBASE、Cochrane系统评价数据库、CENTRAL及临床试验注册库至2018年8月16日。
  • 纳入比较克罗米芬、来曲唑或促性腺激素刺激方案相互之间或与自然周期IUI的随机对照试验,对象为不明原因不孕夫妇。
  • 共纳入26项研究,报告5316名女性,采用多变量随机效应模型进行网络荟萃分析。

主要发现

  • 与自然周期IUI相比,克罗米芬IUI活产/持续妊娠RR 1.05(95%CI 0.63-1.77,低质量证据),来曲唑IUI RR 1.15(95%CI 0.63-2.08,低质量证据),促性腺激素IUI RR 1.46(95%CI 0.92-2.30,低质量证据)。
  • 促性腺激素对比克罗米芬活产/持续妊娠RR 1.39(95%CI 1.09-1.76,中等质量证据),来曲唑对比克罗米芬RR 1.09(95%CI 0.76-1.57,中等质量证据),来曲唑对比促性腺激素RR 0.79(95%CI 0.54-1.15,中等质量证据)。
  • 因高异质性未对多胎妊娠进行网络荟萃分析;成对荟萃分析显示促性腺激素对比自然周期多胎妊娠RR 9.11(95%CI 1.18-70.32),促性腺激素对比克罗米芬RR 1.42(95%CI 0.68-2.97),来曲唑对比克罗米芬RR 0.97(95%CI 0.47-2.01),来曲唑对比促性腺激素RR 0.29(95%CI 0.14-0.58)。
  • 在严格遵循取消标准的研究中,促性腺激素对比克罗米芬活产/持续妊娠RR 1.20(95%CI 0.95-1.51),多胎妊娠RR 0.80(95%CI 0.38-1.68)。

关键数值与推荐

  • 促性腺激素对比克罗米芬活产/持续妊娠RR 1.39(95%CI 1.09-1.76,中等质量证据)。
  • 促性腺激素对比自然周期多胎妊娠RR 9.11(95%CI 1.18-70.32)。
  • 严格取消标准下促性腺激素对比克罗米芬活产/持续妊娠RR 1.20(95%CI 0.95-1.51)。
  • 严格取消标准下促性腺激素对比克罗米芬多胎妊娠RR 0.80(95%CI 0.38-1.68)。

临床怎么用

  • 建议在包含严格取消标准的方案中,使用促性腺激素进行卵巢刺激的IUI。
  • 该建议未考虑成本和患者偏好。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IUI for unexplained infertility can be performed in a natural cycle or in combination with ovarian stimulation. A disadvantage of ovarian stimulation is an increased risk of multiple pregnancies with its inherent maternal and neonatal complication risks. Stimulation agents for ovarian stimulation are clomiphene citrate (CC), Letrozole or gonadotrophins. Although studies have compared two or three of these drugs to each other in IUI, they have never been compared to one another in one analysis. OBJECTIVE AND RATIONALE: The objective of this network meta-analysis was to compare the effectiveness and safety of IUI with CC, Letrozole or gonadotrophins with each other and with natural cycle IUI. SEARCH METHODS: We searched PubMed, MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, CENTRAL and the Clinical Trial Registration Database indexed up to 16 August 2018. We included randomized controlled trials that compared a stimulation regimen with CC, Letrozole or gonadotrophins to each other or to natural cycle IUI among couples with unexplained infertility. We performed the network meta-analysis within a multivariate random effects model. OUTCOMES: We identified 26 studies reporting on 5316 women. The relative risk (RR) for live birth/ongoing pregnancy rates comparing IUI with CC to natural cycle IUI was 1.05 (95% CI 0.63-1.77, low quality of evidence), while comparing IUI with Letrozole to natural cycle IUI was 1.15 (95% CI 0.63-2.08, low quality of evidence) and comparing IUI with gonadotrophins to natural cycle IUI was 1.46 (95% CI 0.92-2.30, low quality of evidence). The RR for live birth/ongoing pregnancy rates comparing gonadotrophins to CC was 1.39 (95% CI 1.09-1.76, moderate quality of evidence), comparing Letrozole to CC was 1.09 (95% CI 0.76-1.57, moderate quality of evidence) and comparing Letrozole to gonadotrophins was 0.79 (95% CI 0.54-1.15, moderate quality of evidence). We did not perform network meta-analysis on multiple pregnancy due to high inconsistency. Pairwise meta-analyses showed an RR for multiple pregnancy rates of 9.11(95% CI 1.18-70.32) comparing IUI with gonadotrophins to natural cycle IUI. There was no data available on multiple pregnancy rates following IUI with CC or Letrozole compared to natural cycle IUI. The RR for multiple pregnancy rates comparing gonadotrophins to CC was 1.42 (95% CI 0.68-2.97), comparing Letrozole to CC was 0.97 (95% CI 0.47-2.01) and comparing Letrozole to gonadotrophins was 0.29 (95% CI 0.14-0.58).In a meta-analysis among studies with adherence to strict cancellation criteria, the RR for live births/ongoing pregnancy rates comparing gonadotrophins to CC was 1.20 (95% CI 0.95-1.51) and the RR for multiple pregnancy rates comparing gonadotropins to CC was 0.80 (95% CI 0.38-1.68). WIDER IMPLICATIONS: Based on low to moderate quality of evidence in this network meta-analysis, IUI with gonadotrophins ranked highest on live birth/ongoing pregnancy rates, but women undergoing this treatment protocol were also at risk for multiple pregnancies with high complication rates. IUI regimens with adherence to strict cancellation criteria led to an acceptable multiple pregnancy rate without compromising the effectiveness. Within a protocol with adherence to strict cancellation criteria, gonadotrophins seem to improve live birth/ongoing pregnancy rates compared to CC. We, therefore, suggest performing IUI with ovarian stimulation using gonadotrophins within a protocol that includes strict cancellation criteria. Obviously, this ignores the impact of costs and patients preference.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Danhof NA, Wang R, van Wely M, et al. IUI for unexplained infertility-a network meta-analysis. Hum Reprod Update. 2020. PMID: 31803930. doi:10.1093/humupd/dmz035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。